725 related articles for article (PubMed ID: 21090841)
1. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
2. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
Robak T
Curr Opin Investig Drugs; 2009 Jun; 10(6):588-96. PubMed ID: 19513948
[TBL] [Abstract][Full Text] [Related]
3. Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions.
Nishida M; Teshigawara K; Niwa O; Usuda S; Nakamura T; Ralph P; Newman R; Padlan EA
Int J Oncol; 2008 Jun; 32(6):1263-74. PubMed ID: 18497988
[TBL] [Abstract][Full Text] [Related]
4. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity.
Natsume A; Shimizu-Yokoyama Y; Satoh M; Shitara K; Niwa R
Cancer Sci; 2009 Dec; 100(12):2411-8. PubMed ID: 19758394
[TBL] [Abstract][Full Text] [Related]
5. Novel CD20 monoclonal antibodies for lymphoma therapy.
Cang S; Mukhi N; Wang K; Liu D
J Hematol Oncol; 2012 Oct; 5():64. PubMed ID: 23057966
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.
Bowles JA; Wang SY; Link BK; Allan B; Beuerlein G; Campbell MA; Marquis D; Ondek B; Wooldridge JE; Smith BJ; Breitmeyer JB; Weiner GJ
Blood; 2006 Oct; 108(8):2648-54. PubMed ID: 16825493
[TBL] [Abstract][Full Text] [Related]
7. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia.
Robak T
Curr Cancer Drug Targets; 2008 Mar; 8(2):156-71. PubMed ID: 18336199
[TBL] [Abstract][Full Text] [Related]
8. Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope.
Uchiyama S; Suzuki Y; Otake K; Yokoyama M; Ohta M; Aikawa S; Komatsu M; Sawada T; Kagami Y; Morishima Y; Fukui K
Cancer Sci; 2010 Jan; 101(1):201-9. PubMed ID: 19930155
[TBL] [Abstract][Full Text] [Related]
9. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.
Rossi EA; Goldenberg DM; Cardillo TM; Stein R; Wang Y; Chang CH
Cancer Res; 2008 Oct; 68(20):8384-92. PubMed ID: 18922911
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
11. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Bornstein GG; Quéva C; Tabrizi M; van Abbema A; Chavez C; Wang P; Foord O; Ahluwalia K; Laing N; Raja S; Wen S; Green LL; Yang X; Webster C; Stewart R; Blakey D
Invest New Drugs; 2010 Oct; 28(5):561-74. PubMed ID: 19626278
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
[TBL] [Abstract][Full Text] [Related]
13. Chicken-derived CD20 antibodies with potent B-cell depletion activity.
Chockalingam K; Kumar A; Song J; Chen Z
Br J Haematol; 2022 Nov; 199(4):560-571. PubMed ID: 36039695
[TBL] [Abstract][Full Text] [Related]
14. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
[TBL] [Abstract][Full Text] [Related]
15. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
[TBL] [Abstract][Full Text] [Related]
16. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Mössner E; Brünker P; Moser S; Püntener U; Schmidt C; Herter S; Grau R; Gerdes C; Nopora A; van Puijenbroek E; Ferrara C; Sondermann P; Jäger C; Strein P; Fertig G; Friess T; Schüll C; Bauer S; Dal Porto J; Del Nagro C; Dabbagh K; Dyer MJ; Poppema S; Klein C; Umaña P
Blood; 2010 Jun; 115(22):4393-402. PubMed ID: 20194898
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies in the treatment of systemic lupus erythematosus.
Robak E; Robak T
Curr Drug Targets; 2009 Jan; 10(1):26-37. PubMed ID: 19149533
[TBL] [Abstract][Full Text] [Related]
18. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils.
van der Kolk LE; de Haas M; Grillo-López AJ; Baars JW; van Oers MH
Leukemia; 2002 Apr; 16(4):693-9. PubMed ID: 11960351
[TBL] [Abstract][Full Text] [Related]
19. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
[TBL] [Abstract][Full Text] [Related]
20. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.
Goldenberg DM; Rossi EA; Stein R; Cardillo TM; Czuczman MS; Hernandez-Ilizaliturri FJ; Hansen HJ; Chang CH
Blood; 2009 Jan; 113(5):1062-70. PubMed ID: 18941114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
